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1. Introduction
Hepatitis C virus (HCV) was identified in 1989 as an 
enveloped virus with a 9.6-kb single-stranded RNA 
genome and a member of the Flaviridae family, genus 
Hepacivirus. It is characterized by a high spontaneous 
mutation rate with an estimated frequency of 1.4–1.9 × 
10³ mutations per nucleotide per year (1, 2). As a result, 
HCV exists as a heterogeneous group of viruses, sharing 
approximately 70% homology. On the basis of nucleotide 
sequence homology, HCV has been classified into no 
fewer than 6 major genotypes and a series of subtypes 
(3). HCV is among the leading causes of chronic liver 
disease worldwide and affects approximately 170 million 
people (4). The severity of the disease that is associated 
with HCV infection varies from asymptomatic, chronic 
infection to cirrhosis and hepatocellular carcinoma 
(5, 6). Combination therapy with pegylated interferon 
alpha and ribavirin (Peg-IFN-α/RBV) for 24–48 weeks 
is the current standard of care in CHC patients (7). 
Unfortunately, more than 40% of patients with chronic 
HCV infection will fail to control viral replication with 
therapy (nonresponders) or will experience a relapse 
when therapy is stopped (relapsers); in addition, it is 
physically and economically demanding. Thus, it is 
crucial to understand the mechanisms of nonresponse 
to overcome it and identify factors that can help predict 
the chances of a patient responding to the treatment. 
The molecular mechanisms that underlie the failure of 
standard therapy are not well understood, but evidence 
indicates that both viral and host factors are involved. 
The focus of interest of this review is to present the 
host factors that are associated with response to the 
current treatment against HCV. Several host factors are 
implicated in modulating the effectiveness of interferon 
therapy for the treatment of HCV infection (8). Likely, 
these host factors play an equally important role in 
modulating the efficacy of interferon therapy. Therefore, 
an understanding of how these factors influence 
interferon therapy may identify therapeutic targets 
to improve the efficacy of interferon therapy (9). Host 
factors that are responsible for responsiveness to HCV 
therapy with Peg-IFN-α/RBV include host genetic factors, 
age, ethnicity, gender, cirrhosis, weight (BMI), steatosis, 
insulin resistance (IR), and type 2 diabetes mellitus 
(T2DM).
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 Implication for health policy/practice/research/medical edu-
cation:
This article reviews the influence of host factors on controlling 
hepatitis C virus. Infectious diseases specialists, hematologists, 
oncologist, hepatologists, and virologists should be aware 
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2. Host Genetic Factors
The mechanism of action of IFN has been characterized, 
and the key points that have been identified are: a) its 
interaction with IFN-α receptor; b) Janus kinase (JAK) signal 
transducer activity; c) STAT phosphorylation; d) synthesis 
of antiviral proteins, such as 2’-5’-oligoadenylate synthetase 
enzyme (5`2` OAS), myxovirus resistance A (MxA) protein 
induced by IFN works like guanosine-5’-triphosphate 
(GTPase) to achieve its antiviral effect. The identification 
of new molecular markers that are related to the response 
to Peg-IFN/RBV represents an important rising concern. 
Our understanding of the genetic basis for this response 
is evolving. Several SNPs from candidate genes have 
been identified to associate with achievement of SVR in 
patients who receive Peg-IFN/RBV treatment. Regulatory 
genes of IFN antiviral activity, immune response genes, 
and genes that are implicated in obesity or IR have been 
analyzed. Intracellular MxA seems to be the most specific 
marker of the antiviral activity of IFN (10). The -88T SNP 
in the MxA gene was found to be associated with lower 
MxA activity. In patients with low viral load, sustained 
viral response (SVR) was significantly higher (62%) in 
-88T patients than in patients bearing the -88A allele 
(32%) (11). The 5`2` OAS plays a major role in the clearance 
of the virus. However, some studies that included an 
analysis of the GG genotype (in the 3’UTR region) did not 
predict SVR (12). Lastly, a tandem repeat of 3 nucleotides 
in the protein kinase R gene, considered “large” when 
containing > 9 repeats, has been found to be associated 
with SVR. The large/large polymorphism was seen more 
often in patients achieving SVR than in nonresponders 
(89.4% vs. 71.8% ; P = 0.017) (13). Apolipoprotein E has been 
implicated in the entry of HCV into the cell via the LDL 
receptor. In a cohort of 506 patients treated with Peg-IFN/
RBV, the €4 allele was found to be associated with poorer 
response in patients with genotype 1 (30% vs. 42% ; P < 
0.05) (13). Several polymorphisms in proinflammatory 
cytokines have been examined as candidate genes in the 
prediction of SVR. The biallelic polymorphism in tumor 
necrosis factor (TNF) (-238 and -308) does not appear 
to be associated with SVR (14). TGF-1 and interleukin-10 
polymorphisms have been strongly related to achieving 
an SVR. The -29C/C genotype in TGF-beta1 promotes 
resistance to Peg-IFN/RBV treatment (15). In a multivariate 
analysis of 105 patients who were treated with Peg-
IFN/RBV, HLA class I B44 was seen to be independently 
associated with an improved SVR to combined Peg-IFN/
RBV, together with the viral non-1 genotype.
Although the potential value of these well-selected 
candidate genes and relevance of some of their 
associations were confirmed after a multivariate 
analysis, the majority of them had a minor impact on 
clinical practice, and they have not been included in the 
daily management of patients with chronic hepatitis 
C. Several pharmacogenetic/genomewide association 
studies (GWASs) on response to HCV treatment have 
identified a relationship between several polymorphisms 
in interferon lambda (IFN-X), transduced from the IL28B 
gene (19q13) region, and SVR. Ge et al. (16) analyzed 1137 
patients with HCV genotype 1 infection and identified 
several SNPs near the IL-28B gene on chromosome 19 
that were significantly more common in responders 
than nonresponders. Moreover, the distributions of this 
CC genotype in were strongly related to SVR in Asians, 
Europeans, Hispanic, and African-Americans. These 
results have since been confirmed in many series (17-18). 
A study by Thomas et al. (19) reported that the same IL-
28B variant that was described by Ge and coworkers was 
associated with spontaneous clearance of HCV. A strong 
association of rs12979860 with both EVR and SVR in IFN-
naive patients who were treated with Peg-IFNα- 2a/RBV 
has also been reported (20). Further, this polymorphism 
has been strongly associated with the possibility of 
achieving SVR in patients who have been infected by 
genotype 1, without rapid virological response (21). A 
recent meta-analysis confirmed the association between 
genotype CC rs12987960 and SVR (OR:4.5, 95% CI: 2.8-7.3) 
(22). Conversely, the role of the IL28B polymorphism is 
unknown in patients with a non-1 chronic hepatitis C 
genotype regarding its association with SVR rates. The 
IL28B polymorphism rs8099917 G is not associated with 
higher SVR rates. In 230 patients with genotype 2 or 3 who 
received Peg-IFN/RBV, the CC genotype predicted SVR in 
patients without rapid virological response (clearance of 
the virus after 4 weeks of treatment) but not in the overall 
cohort (23). In a multivariate analysis of HCV-4 patients, 
baseline viral load, fibrosis, and the IL28 T allele (OR: 
0.124, 95% CI.: 0.030-0.505) were significantly associated 
with SVR (24). However, the strongest predictor of final 
outcome was RVR (OR: 26.00; 95% CI: 7.148-94.545, P < 
0.0001). If RVR was included in the multivariate model, 
only the RVR and fibrosis score remained significant. 
Thus, determining the IL28 polymorphism may not be 
useful in selecting patients with HCV-4 for abbreviated 
treatment schedules (24). However, larger prospective 
studies are warranted before we can determine the 
predictive value of IL28B in HCV-4.
IL28 polymorphisms are highly promising genetic 
markers, but the role of genetic alterations in patients 
who are infected by non-1 genotypes should be further 
demonstrated. On the other hand, from a clinical point 
of view, approximately one-third of patients bearing 
the CC genotype (rs12979860) did not achieve SVR, 
while nearly half of CT heterozygotes and one-third of 
TT homozygous individuals could achieve an SVR when 
treated with Peg-IFN/RBV (22). Thus, genetic factors that 
modulate (positively or negatively) the effect of this 
polymorphism on sustained responses warrant further 
exploration. Other genetic markers could explain this 
gap between IL28B genotype and sustained response 
(25).237 Hepat Mon. 2012;12(4)
Host Factors Impact on HCV Khattab MA E et al.
3. Age
Patient age is another factor that is associated with 
responsiveness to Peg-IFN-α/RBV therapy in chronic 
HCV infection. Generally, it is believed that younger 
individuals (usually < 40 years of age) respond better to 
IFN-α treatment than older persons (26, 27). In a recent 
study evaluating the predictors of SVR for HCV genotype 1 
patients who were enrolled in 2 phase III studies with PEG-
IFNα-2a, Reddy and coworkers (26) showed that patients 
aged > 50 years had poorer responses to combined 
therapy than patients aged < 50 years. Interestingly, the 
lower SVR rates in older patients resulted primarily from 
a higher relapse rate. The importance of considering age 
in a patient who is initiating therapy for HCV has been 
highlighted by a recent study by Davis and coworkers (28), 
who developed a multicohort natural history model for 
predicting disease outcomes and the benefits of therapy 
in HCV-infected patients. The obvious explanation is that 
older HCV patients are likely to have more advanced 
liver disease, such as fibrosis and cirrhosis (themselves 
predictors of poor virological responses). Impairments 
in cellular, humoral, and innate immunity in the elderly 
may be another important factor that is responsible for 
decreasing successful responses to IFN-α treatment in 
older patients (29).
4. Metabolic Syndrome
Chronic hepatitis C (CHC) can be considered not 
only a viral disease but also a special type of metabolic 
disease. CHC interacts with lipid metabolism, leading to 
steatosis; impairs glucose metabolism, leading to IR and 
T2DM; and is associated with an increased risk of carotid 
atherosclerosis (30). This combination of favorable 
lipids and diabetes is unusual, as the conventional 
metabolic syndrome, a constellation of risk factors for 
atherosclerosis, includes, among others, an atherogenic 
lipid profile, glucose intolerance, and IR (31).
5. Insulin Resistance
There is a complex interaction between HCV infection 
and insulin sensitivity (32). Hepatitis C core protein 
promotes the degradation of insulin receptor substrate-1 
and induces IR. IR, obesity, and steatosis are also 
associated with a higher risk of fibrosis progression (33, 
34). Increasing levels of IR are associated with reduced 
rates of rapid virological response (35, 36) and SVR in 
patients with HCV genotypes 1, 2, 3, and 4 infections who 
are treated with a combination of Peg-IFN-α and RBV 
(33, 37-39). However, the mechanisms of IR-induced IFN 
resistance are not completely understood. Intracellular 
factors that are dysregulated by HCV and are responsible 
for the insulin-resistant phenotype may have additional 
effects, as they are also involved in regulating IFN-α 
signaling (Figure 1). These factors include some members 
of the suppressor of cytokine signaling (SOCS) family 
(40-42) and protein phosphatase 2A (PP2A) (43). Recent 
studies have indicated that SOCS-3 plays a crucial role. 
SOCS-3 is known to suppress insulin signaling through 
the ubiquination of insulin receptor substrates 1 and 2 
(IRS) and cause IR (38). Recently, Vanni et al. reported an 
increase in intrahepatic SOCS-3 mRNA expression with 
hepatic IR (44). SOCS-3 also inhibits the IFN-induced 
JAK signal transducer and suppresses the expression of 
antiviral proteins, including 2,5-OAS and MxA (45, 46). 
Hepatic expression of SOCS-3 increases significantly in 
nonresponder patients compared with responders (46). 
Specifically, a genetic polymorphism of SOCS-3 (the 4874 
AA genotype) is strongly associated with nonresponse 
to antiviral therapy (40). Further, the reduced hepatic 
response to IFN in HCV-infected chimpanzees is 
mediated via the activation of SOCS-3 (47, 48), and hepatic 
expression of SOCS-3 predicts the outcome of antiviral 
therapy  (46).  IR is known to increase hepatic lipid 
synthesis (49). Since the lipid droplet is an important 
organelle for HCV replication (50), the accumulation of 
hepatic lipid droplets may increase HCV replication and 
result in poor responses to antiviral treatment. As such, 
host and viral factors are involved in the development 
of IR and, as a consequence, affect antiviral therapy. The 
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use of insulin-sensitizing agents, such as pioglitazone, in 
HCV treatment increases both SVR and RVR rates (51).
6. Diabetes
As with IR, individuals with T2DM are less likely to 
achieve SVR (52, 53). In addition, diabetics are more 
likely to experience side effects of the treatment (51). 
Compounding this phenomenon, fibrosis progresses 
more rapidly in diabetics; hence, cirrhosis-free survival 
rates are significantly lower in diabetics than in 
nondiabetics (54, 55).
7. Lipid Profiles
Lipid profiles and virological response to antiviral 
treatment were recently correlated in many studies. 
In a recent study from Japan on the lipid fractions 
(20 subfractions based on particle size) from 44 CHC 
patients demonstrated that high triglyceride (TG) 
content of very low-density lipoproteins (VLDL) was 
strongly predictive of a better response to treatment 
(56). In another large European cohort of 575 HCV 
genotype 1-infected patients, baseline low-cholesterol 
levels were an independent predictor of a lack of SVR (P = 
0.084), but the authors failed to observe any difference in 
baseline TG levels according to SVR. In spite of the drop 
in cholesterol level in patients while they were receiving 
antiviral treatment, cholesterol levels rebounded to 
either above baseline or to baseline in patients with SVR 
and nonresponders/relapsers, respectively; (P = 0.02). 
Triglyceride levels in patients with and without SVR 
differed only at follow-up (P = 0.028) (57). A large German, 
observational, real-world study enrolled 10,390 patients 
who were treated with PegIFN-α2a/RBV and evaluated 
and prospectively followed them for cardiovascular and 
metabolic risk markers, concluding that in contrast to 
the presence of T2DM, which was a negative predictor of 
SVR, the presence of elevated total cholesterol levels was 
associated with higher SVR rates (58).
In another trial that assessed the influence of race on 
the effect of lipid profiles on SVR, a recent analysis from 
the Virahep-C study, a prospective study of treatment-
naive patients with genotype 1 HCV infection who 
received PegIFN-α2a/RBV therapy for 48 weeks, observed 
that pretreatment TG and low-density lipoprotein 
cholesterol (LDL-C) levels were inversely and directly 
related to SVR rate, respectively. Yet, baseline LDL-C was 
significantly higher in Caucasian-Americans compared 
with African-Americans, although the difference in these 
parameters did not explain the difference in treatment 
response between races (59).
There have been 2 recent novel findings from a 
retrospective analysis of 1604 patients in the IDEAL trial 
(Individualized Dosing Efficacy vs. Flat Dosing to Assess 
Optimal Pegylated Interferon Therapy): 1. despite high 
LDL-C and low HDL-C levels, statin use was independently 
associated with SVR (60); and 2. in a genetic analysis of 
the association between serum lipid levels and hepatic 
steatosis in CHC patients, Clark and coworkers identified 
4 ingle nucleotide polymorphism (SNPs) in the IL28B 
gene region that were significantly associated with 
pretreatment LDL (top SNP rs12980275, P = 10-17, good IFN 
response variant = higher LDL). In a logistic regression 
model, baseline LDL was strongly associated with SVR. 
However; including rs12980275 as a covariate attenuated 
the effect of LDL. Interestingly, this genetic association 
persisted after treatment for nonresponders, not for 
patients with SVR. The authors concluded that the poor 
response with the IL28B variant was strongly associated 
with lower pretreatment LDL levels and greater hepatic 
steatosis (61). In accordance with these findings, another 
recent trial from Japan showed that the TT genotype of 
the rs8099917 polymorphism near the IL28B gene was 
associated with high LDL cholesterol levels, in addition 
to a high frequency of mutations in the interferon 
sensitivity-determining region and a wild type of core aa 
70; this pattern was the most significant predictive factor 
of a lack of response to PEG-IFN-α/RBV in genotype 1b 
CHC patients with high viral loads (62). These intriguing 
data may help to provide an explanation for the series of 
clinical observations linking higher LDL, less steatosis, 
and SVR.
8. Hepatic Steatosis
Hepatic steatosis is commonly observed (63) and is 
an independent risk factor for disease progression in 
patients with HCV infection (31).  Various studies have 
shown that both host and viral factors may contribute 
to the development of steatosis, with the relative 
importance of each varying with HCV genotype. In 
particular, in patients who are infected with genotype 
3, steatosis is mostly virus-induced and often severe. 
In contrast, in those with non-genotype 3, steatosis 
is mainly associated with host metabolic factors and 
correlates with body mass index (BMI) and central 
adiposity (64, 65). It has been shown in large clinical 
trials that steatosis impairs the response to antiviral 
therapy (65, 66). The effect, however, is more pronounced 
in patients with the non-3a genotype (55, 56), implicating 
IR as the mechanism that affects the response to IFN-α 
and suggesting that viral steatosis does not impair the 
response to treatment (67, 68). It is worth noting that 
patients with CHC with virally induced steatosis do not 
have increased IR levels relative to patients without 
steatosis (69).
9. Menopause and Response to Antiviral 
Treatment
In recent data, a large cohort of 1000 consecutive 
patients with compensated liver disease from CHC who 
were receiving standard PEG-IFN-α/RBV treatment were 239 Hepat Mon. 2012;12(4)
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analyzed for predictors of SVR—menopause correlated 
with not only more severe liver disease, with high 
necroinflammatory features, and a high rate of hepatic 
steatosis but also a low likelihood of SVR in the entire 
female cohort and in a subgroup of HCV genotype 1 
females, probably due to inflammatory factors, such 
as IL-6 and TNF-α, which modulate at menopause (70). 
Despite being upregulated in female patients, these 
cytokines underwent a further and significant increase 
at the time of menopause, both circulating and hepatic 
levels. Ongoing studies are assessing whether the use 
of hormonal replacement therapy is associated with 
improved SVRs.
10. Host Factors and Individualization of 
Therapy 
In an effort to improve the rates of sustained response 
to therapy for CHC, various strategies have been used to 
tailor treatment durations. In addition to depending 
on treatment responses, recent expert panels have 
recommended host factors, such as complementary 
factors, in improving tailoring treatment durations in 
HCV-4 patients (71) (Figure 2). With the emergence of new 
data on IL28B, it is expected to be involved in upcoming 
trials to update these algorithms. 
In conclusion, besides viral factors, several host factors 
are responsible for the responsiveness to HCV therapy 
with Peg-IFN-α/RBV, including host genetic factors, age, 
ethnicity, gender, menopause, cirrhosis, BMI, steatosis, 
IR, and T2DM. These factors now are enrolled in all of the 
algorithms for the individualization of therapy.
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